Other RTKs Our outcomes demonstrate that HIRmAb-GDNF dosing within a monkey style of PD isn’t a highly effective neuroprotective strategy and could present serious health threats that needs to be considered when setting up future usage of the IR antibody being a carrier, or of any systemic treatment of a GDNF-containing molecule tuskonus July 7, 2022